Jiangsu Gdk Biotechnology Stock Current Valuation
| 688670 Stock | 16.29 0.49 3.10% |
Valuation analysis of Jiangsu GDK Biotechnology helps investors to measure Jiangsu GDK's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Jiangsu GDK's Cash And Short Term Investments are projected to increase significantly based on the last few years of reporting. The current year's Free Cash Flow is expected to grow to about 28.2 M, whereas Cash is forecasted to decline to about 59.9 M. Fundamental drivers impacting Jiangsu GDK's valuation include:
Price Book 1.4773 | Enterprise Value 1.7 B | Enterprise Value Ebitda 151.2079 | Price Sales 38.1206 | Enterprise Value Revenue 32.5125 |
Overvalued
Today
Please note that Jiangsu GDK's price fluctuation is somewhat reliable at this time. Calculation of the real value of Jiangsu GDK Biotechnology is based on 3 months time horizon. Increasing Jiangsu GDK's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Jiangsu GDK is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Jiangsu Stock. However, Jiangsu GDK's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 16.29 | Real 12.55 | Hype 16.29 |
The real value of Jiangsu Stock, also known as its intrinsic value, is the underlying worth of Jiangsu GDK Biotechnology Company, which is reflected in its stock price. It is based on Jiangsu GDK's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Jiangsu GDK's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Jiangsu GDK Biotechnology helps investors to forecast how Jiangsu stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Jiangsu GDK more accurately as focusing exclusively on Jiangsu GDK's fundamentals will not take into account other important factors: Jiangsu GDK Biotechnology Company Current Valuation Analysis
Jiangsu GDK's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Jiangsu GDK Current Valuation | 1.71 B |
Most of Jiangsu GDK's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jiangsu GDK Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Jiangsu GDK Biotechnology has a Current Valuation of 1.71 B. This is 88.08% lower than that of the Biotechnology sector and 63.15% lower than that of the Health Care industry. The current valuation for all China stocks is 89.7% higher than that of the company.
Jiangsu Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jiangsu GDK's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jiangsu GDK could also be used in its relative valuation, which is a method of valuing Jiangsu GDK by comparing valuation metrics of similar companies.Jiangsu GDK is currently under evaluation in current valuation category among its peers.
Jiangsu Fundamentals
| Return On Equity | -0.0825 | ||||
| Return On Asset | -0.0601 | ||||
| Profit Margin | (2.15) % | ||||
| Operating Margin | (0.33) % | ||||
| Current Valuation | 1.71 B | ||||
| Shares Outstanding | 123.2 M | ||||
| Shares Owned By Insiders | 76.73 % | ||||
| Shares Owned By Institutions | 2.56 % | ||||
| Price To Book | 1.48 X | ||||
| Price To Sales | 38.12 X | ||||
| Revenue | 134.59 M | ||||
| Gross Profit | 267.9 M | ||||
| EBITDA | (129.69 M) | ||||
| Net Income | (70.99 M) | ||||
| Total Debt | 64.06 M | ||||
| Book Value Per Share | 10.70 X | ||||
| Cash Flow From Operations | 80.9 M | ||||
| Earnings Per Share | (0.92) X | ||||
| Number Of Employees | 451 | ||||
| Beta | 0.27 | ||||
| Market Capitalization | 2.01 B | ||||
| Total Asset | 1.63 B | ||||
| Retained Earnings | 105.24 M | ||||
| Working Capital | 494.91 M | ||||
| Net Asset | 1.63 B |
About Jiangsu GDK Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jiangsu GDK Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jiangsu GDK using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jiangsu GDK Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Jiangsu Stock
Jiangsu GDK financial ratios help investors to determine whether Jiangsu Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jiangsu with respect to the benefits of owning Jiangsu GDK security.